Swedish Orphan Biovitrum AB (publ) (https://www.sobi.com/en/investors/fda
-approves-gamifantr-emapalumab-first-and-only-treatment-primary-haemophagocytic)
(Sobi™) (STO:SOBI) announces today that revenue and EBITA for the full year 2019
were higher than previous estimates. Full-year revenue was approximately SEK
14,150 -14,250 M and EBITA approximately SEK 6,200 - 6,300 M, excluding
restructuring costs and excluding impact from the acquisition of Dova
Pharmaceuticals. The main reasons for the better performance are:
· Significantly higher sales of Synagis following increased demand as a result
of improved commercial effectiveness and wholesaler stocking. In addition, sales
increased due to a positive Gross-to-Net impact and a more severe RSV season
than normal
· Higher Gamifant sales reflecting higher average patient weight and longer
treatment periods
· Better performance of Orfadin and other Specialty Care products mainly due
to phasing of large orders.
The main period of the RSV season spans from the fourth quarter to the first
quarter why sales of Synagis shall be evaluated over a full period (Q4-Q1).
Gamifant is still in launch phase and continued volatility is expected going
forward due to the ultra-rare nature of the disease and the limited patient
population.
At the publication of the Q3 2019 report on 31 October Sobi reiterated the
outlook for the FY year 2019 published on 17 July 2019. Revenue for the full
year was expected to be in the range of SEK 13,000 - 13,500 M and EBITA for the
full year was expected to be in the range of SEK 5,300 - 5,500 M[ ]excluding
restructuring costs and excluding impact from the acquisition of Dova
Pharmaceuticals.
Sobi will announce its fourth quarter and full year 2019 report on Thursday 13
February 2020 at 8:00 am CET.
About Sobi
Sobi is a specialised international biopharmaceutical company transforming the
lives of people with rare diseases. Sobi is providing sustainable access to
innovative therapies in the areas of haematology, immunology and specialty
indications. Today, Sobi employs approximately 1,300 people across Europe, North
America, the Middle East, Russia and North Africa. In 2018, Sobi's revenues
amounted to SEK 9.1 billion. Sobi's share (STO:SOBI) is listed on Nasdaq
Stockholm. You can find more information about Sobi at sobi.com.
This information is information that Swedish Orphan Biovitrum AB (publ) is
obliged to make public pursuant to the EU Market Abuse Regulation. The
information was submitted for publication, through the agency of Linda
Holmström, Corporate Communications and Investor relations at 19:00 CET on 16
January 2020.
For more information please contact
Paula Treutiger, Head of Communication & Investor Relations
+ 46 733 666 599
paula.treutiger@sobi.com
Linda Holmström, Corporate Communication & Investor Relations
+ 46 708 734 095
linda.holmstrom@sobi.com
Swedish Orphan Biovitrum AB (publ)
Postal address SE-112 76 Stockholm, Sweden
Phone: 46 8 697 20 00 www.sobi.com
Attachments:
01160575.pdf
Attachments
- Original document
- Permalink
Disclaimer
NASDAQ OMX Nordic - NASDAQ OMX Stockholm AB published this content on 16 January 2020 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 16 January 2020 18:03:08 UTC
